|Videos|July 5, 2022

Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma

“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.

James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME